CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell Therapeutics

CERo is an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms. Its lead product candidate is expected to... | June 5, 2023

Related Keywords

Russia ,Phoenix ,Arizona ,United States ,Ukraine ,Briang Atwood ,Daniel Corey ,Chris Ehrlich ,Nasdaq ,Cero Therapeutics Holdings Inc ,Phoenix Biotech Acquisition Corp ,Goodwin Procter ,Merger Sub Inc ,Company Capital ,Cero Therapeutics Inc ,Exchange Commission ,J Vb Financial Group ,Technology Officer ,Ellenoff Grossman Schole ,Phoenix Biotech Acquisition ,Therapeutics Holdings ,Nasdaq Capital Market ,Chief Executive Officer ,Chief Financial Officer ,Chief Operating Officer ,Chief Technology ,Current Report ,Ellenoff Grossman ,Company Capital Markets ,Financial Group ,Biotech Acquisition ,Business Combination ,Registration Statement ,Business Combination Agreement ,Merger Sub ,Quarterly Report ,Phoenix Biotech Acquisition Corp Stock Exchange ,News ,Information ,Press Release ,Hero ,Us ,N ,Nnovative ,Immunotherapy ,Company ,Seeking ,O ,Advance ,The ,Text ,Generation ,F ,Engineered , ,Fell ,Herapeutics ,Hat ,Employ ,Hagocytic ,Its ,Head ,Product ,Candidate ,Xpected Pbax Us71902k1051 ,